[BCLI] Brainstorm Cell Therapeutics Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2.58 Change: 0.08 (3.2%)
Ext. hours: Change: 0 (0%)

chart BCLI

Refresh chart

Strongest Trends Summary For BCLI

BCLI is in the medium-term up 20% in 7 months.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson?s disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The company?s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor and brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. It is developing NurOwn, an autologous adult stem cell product for the treatment of ALS. Brainstorm Cell Therapeutics Inc. also has agreements with Hadasit Medical Research Services and Development Ltd.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.27 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-16.37
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-41.86% ROE-47.66% ROI
Current Ratio8.1 Quick Ratio Long Term Debt/Equity Debt Ratio0.14
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities14.74 M Cash From Investing Activities-13.56 M Cash From Operating Activities-1.94 M Gross Profit
Net Profit-2.24 M Operating Profit-2.21 M Total Assets22.39 M Total Current Assets22.08 M
Total Current Liabilities2.73 M Total Debt Total Liabilities2.73 M Total Revenue
Technical Data
High 52 week5.19 Low 52 week2.98 Last close3.89 Last change1.57%
RSI40.54 Average true range0.12 Beta0.21 Volume94.48 K
Simple moving average 20 days-1.31% Simple moving average 50 days-3.38% Simple moving average 200 days4.71%
Performance Data
Performance Week-1.52% Performance Month1.83% Performance Quart-2.26% Performance Half26.71%
Performance Year18.6% Performance Year-to-date9.58% Volatility daily1.82% Volatility weekly4.07%
Volatility monthly8.34% Volatility yearly28.91% Relative Volume272.01% Average Volume61.75 K
New High New Low

News

2019-05-31 01:00:00 | BrainStorm Presents Poster at Consortium of Multiple Sclerosis Centers CMSC 33rd Annual Meeting

2019-05-30 01:00:00 | BrainStorm Announces Second Clinical Site to Enroll Patients in Its Progressive MS Phase 2 Study

2019-05-28 01:00:00 | BrainStorm Senior Management to Present at BIO 2019

2019-05-21 10:15:00 | BCLI: Enrollment in Phase 3 ALS Trial to Complete in 3Q19…

2019-05-13 01:00:00 | BrainStorm CEO to Present at the World Advanced Therapy and Regenerative Medicine Congress in London

2019-05-10 17:00:00 | BrainStorm Announces Financial Results for the First Quarter of 2019 and Provides a Corporate Update

2019-04-30 04:00:00 | BrainStorm’s Cellular Technology Platform Expanded to Include Exosomes for Neurodegenerative Diseases

2019-04-04 10:30:00 | BCLI: Two Abstracts to be Presented at AAN Annual Meeting…

2019-03-28 04:30:00 | Two BrainStorm Scientific Abstracts Accepted for Presentation at the 71st American Academy of Neurology Annual Meeting

2019-03-26 06:30:00 | BrainStorm Announces Grant of an additional New European Patent for NurOwn®

2019-03-18 22:26:33 | Atlas Blockchain Announces Definitive Agreement for the Acquisition of Isracann and Amendment to Investor Services Agreement

2019-03-15 10:50:00 | BCLI: Hospital Exemption Approved in Israel; First Patient Enrolled in Phase 2 Study in Progressive MS…

2019-03-14 01:00:00 | BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS

2019-03-13 11:57:09 | Breakeven On The Horizon For Brainstorm Cell Therapeutics Inc. NASDAQ:BCLI

2019-03-12 07:47:54 | The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug

2019-03-07 04:00:00 | BrainStorm to Host Business Update Conference Call

2019-02-22 07:30:00 | BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study

2019-02-21 06:00:00 | BrainStorm to Present at 2019 Sachs Associates European Life Sciences CEO Forum in Zurich, Switzerland

2019-02-19 08:06:49 | BrainStorm Issues a Statement to Patients and Shareholders

2019-02-04 08:22:51 | BrainStorm to Present at 2019 BIO CEO & Investor Conference and Extracellular Vesicles in Diagnostics & Therapeutics Symposium

2019-01-25 07:15:00 | BrainStorm Cell Therapeutics to Present at the 2019 NobleCon15 Annual Investor Conference in Fort Lauderdale, Florida

2019-01-22 08:40:00 | BrainStorm Granted Additional Patent for NurOwn® in Israel

2019-01-11 00:05:00 | BrainStorm to Present NurOwn® Phase 3 Study Update at the 9th Annual California ALS Research Summit in Irvine, CA

2019-01-07 13:30:00 | BCLI: Initiating Phase 2 Study in Progressive Multiple Sclerosis…

2019-01-03 06:04:03 | BrainStorm Cell Therapeutics to Present at the 2019 Biotech Showcase and Sachs Associates Neuroscience Innovation Forum at JPM Week

2018-12-27 07:35:00 | BrainStorm Issues 2018 Letter to Shareholders

2018-12-26 01:00:00 | BrainStorm Expands Manufacturing of NurOwn® for Phase 2 Progressive MS Trial

2018-12-17 07:34:12 | FDA Accepts BrainStorm’s NurOwn® IND Application for Progressive Multiple Sclerosis

2018-12-17 07:21:25 | BrainStorm gets FDA okay for stem cell trial in MS patients

2018-12-04 08:00:00 | BrainStorm Cell Therapeutics to Present at the 29th International Symposium on ALS/MND

2018-12-03 13:53:08 | Do Institutions Own Brainstorm Cell Therapeutics Inc NASDAQ:BCLI Shares?

2018-11-21 08:30:00 | Detailed Research: Economic Perspectives on Stellar Biotechnologies, MAM Software Group, EverQuote, Brainstorm Cell Therapeutics, Mid-Con Energy Partners, LP, and Staffing 360 Solutions — What Drives Growth in Today's Competitive Landscape

2018-11-19 08:00:00 | BrainStorm Cell Therapeutics Announces Submission of IND for NurOwn® in Progressive Multiple Sclerosis

2018-11-07 08:00:00 | BrainStorm Cell Therapeutics to Present at November Clinical and Investor Conferences

2018-10-30 10:15:00 | BCLI: Phase 3 Trial to Be Fully Enrolled by Mid-2019…

2018-10-29 08:00:00 | BrainStorm Announces Financial Results for the Third Quarter of 2018 and Provides a Corporate Update

2018-10-17 08:30:00 | BrainStorm to Announce Third Quarter Financial Results and Provide Corporate Update on Monday, October 29

2018-10-04 11:23:12 | Does Brainstorm Cell Therapeutics Inc NASDAQ:BCLI Fall With The Market?

2018-10-03 06:10:26 | BrainStorm Highlights Translational Data and Presentations Supporting NUROWN® Technology Platform as a Best-In-Class Strategy in ALS

2018-09-13 07:30:00 | BrainStorm Granted New U.S. Patent for Industrial Scale Manufacturing of NurOwn®

2018-09-12 08:49:52 | BrainStorm to Present at FDA and Scientific Workshops Highlighting Innovation in ALS Trial Designs and Continued Progress with NurOwn® Cellular Therapy Platform

2018-09-05 11:36:02 | BrainStorm Cell Therapeutics Announces New Presentation Time at the H.C. Wainwright & Co. 20th Annual Investor Conference

2018-09-04 08:00:00 | BrainStorm Appoints Arturo Araya as Chief Commercial Officer

2018-08-29 08:00:00 | BrainStorm Cell Therapeutics to Provide Corporate Update at the H.C. Wainwright & Co 20th Annual Investor Conference

2018-08-23 10:45:00 | BCLI: Positive Interim Safety Analysis for Phase 3 Trial…

2018-08-23 08:20:00 | BrainStorm Cell Therapeutics Announces Successful Interim Safety Analysis in Phase 3 Trial of NurOwn® Therapy for ALS

2018-07-25 09:03:00 | BrainStorm Announces Grant of a New European Patent for NurOwn®

2018-07-24 10:05:00 | BCLI: Phase 3 Trial in ALS Fully Funded; Company to Announced Additional Indications for NurOwn

2018-07-23 08:00:00 | BrainStorm Announces Financial Results for the Second Quarter of 2018 and Provides a Corporate Update

2018-07-23 06:30:00 | Brainstorm Cell Therapeutics Inc. to Host Earnings Call